Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Form 4	PHARMACEU	TICALS I	NC							
May 22, 20								OMB A	PPROVAL	
FORM	UNITED	STATES		RITIES A shington			COMMISSION		3235-0287	
Check th if no lor subject to Section Form 4 Form 5 obligation may con	so 16. or Filed pur ^{Dns} section 17(suant to S (a) of the I	Section Public U	SECUI	RITIES ne Securit ding Con	WNERSHIP OF nge Act of 1934, of 1935 or Sectio 940	Expires: January 31, 2005 Estimated average burden hours per response 0.5			
<i>See</i> Inst 1(b).	ruction	()								
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> ABERCROMBIE GEORGE B			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]			5. Relationship of Reporting Person(s) to IssuerS (Check all applicable)				
(Last) (First) (Middle) PO BOX 16069			3. Date of Earliest Transaction (Month/Day/Year) 05/20/2015				_X_ Director10% Owner Officer (give titleOther (specify below)below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
CHAPEL I	HILL, NC 27516						Person	wore than one R	porting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	4. Securiti nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	for each cl	ass of sec	urities bene	Perso inform requir	ns who rest nation cont ed to resp ys a curre	or indirectly. spond to the collectained in this form ond unless the for ntly valid OMB col	i are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securiti
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amor or Numl of Sh
Automatic Stock Option Grant (1)	\$ 11.39	05/20/2015		А		15,000		06/20/2015 <u>(2)</u>	05/20/2025	Common Stock	15,0

Reporting Owners

Reporting Owner Name / Address	Relationships							
1 0	Director	10% Owner	Officer	Other				
ABERCROMBIE GEORGE B PO BOX 16069 CHAPEL HILL, NC 27516	Х							
Signatures								
/s/ Alane P. Barnes, by power of attorney	f	05/22/	2015					

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

(2) Vests 1/12th per month over twelve months beginning June 20, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.